Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by on Jul 11th, 2026

Precision BioSciences, Inc. (NASDAQ:DTIL – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $32.25.

DTIL has been the subject of several research analyst reports. JonesTrading reaffirmed a “buy” rating and set a $30.00 price target on shares of Precision BioSciences in a research note on Friday, April 17th. HC Wainwright reissued a “buy” rating on shares of Precision BioSciences in a research note on Thursday. Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. Oppenheimer started coverage on Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 target price for the company. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $19.00 target price on shares of Precision BioSciences in a report on Friday, March 13th.

Check Out Our Latest Stock Report on DTIL

Precision BioSciences Trading Down 4.4%

Shares of NASDAQ DTIL traded down $0.40 during mid-day trading on Friday, reaching $8.76. The company had a trading volume of 579,601 shares, compared to its average volume of 575,431. The stock has a market cap of $226.01 million, a price-to-earnings ratio of -2.39 and a beta of 1.25. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $9.62. The business’s 50-day moving average is $7.31 and its 200-day moving average is $5.86. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29.

Precision BioSciences (NASDAQ:DTIL – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.09). The company had revenue of $10.84 million during the quarter, compared to analysts’ expectations of $4.05 million. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 85.37%. Equities analysts expect that Precision BioSciences will post -2.21 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its position in Precision BioSciences by 167.6% during the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock valued at $151,000 after purchasing an additional 17,172 shares during the period. Quantinno Capital Management LP purchased a new position in Precision BioSciences during the first quarter valued at approximately $104,000. Octagon Capital Advisors LP raised its stake in Precision BioSciences by 16.6% in the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock worth $12,302,000 after buying an additional 318,737 shares in the last quarter. Affinity Asset Advisors LLC purchased a new stake in Precision BioSciences during the first quarter worth $3,289,000. Finally, XTX Topco Ltd bought a new stake in Precision BioSciences during the 4th quarter valued at $149,000. 37.99% of the stock is currently owned by institutional investors.

Precision BioSciences Company Profile

(Get Free Report)

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.

Featured Articles

Analyst Recommendations for Precision BioSciences (NASDAQ:DTIL)

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.